Table 1.
Baseline Patient Characteristics of HCC Patients with EHC Blood Supplies
| Patient Characteristics | All | DEB-TACE | cTACE | p-value |
|---|---|---|---|---|
| Number | 61 | 42 | 19 | |
| Gender | 0.077 | |||
| Male | 50 (82.0%) | 32 (76.2%) | 18 (94.7%) | |
| Female | 11 (18.0%) | 10 (23.8%) | 1 (5.3%) | |
| Causes of HCC | 0.413 | |||
| HBV | 35 (57.4%) | 26 (61.9%) | 9 (47.4%) | |
| HCV | 14 (23.0%) | 7 (16.7%) | 7 (36.8%) | |
| HBV+HCV | 4 (6.6%) | 3 (7.1%) | 1 (5.3%) | |
| Others | 8 (13.0%) | 6 (14.3%) | 2 (10.5%) | |
| Median age (years) | 65.0 (27.0–87.6) |
63.7 (27.0–86.0) |
67.4 (41.0–87.6) |
0.289 |
| Child–Pugh class | 0.485 | |||
| A | 51 (83.6%) | 34 (81.0%) | 17 (89.5%) | |
| B | 10 (16.4%) | 8 (19.0%) | 2 (10.5%) | |
| BCLC stage | 0.160 | |||
| A B |
33 (54.1%) 16 (26.2%) |
20 (47.6%) 14 (33.3%) |
13 (68.4%) 2 (10.5%) |
|
| C | 12 (19.7%) | 8 (19.1%) | 4 (21.1%) | |
| ECOG performance | 0.121 | |||
| 0 | 44 (72.1%) | 32 (71.4%) | 12 (68.4%) | |
| 1 | 17 (27.9%) | 10 (28.6%) | 7 (31.6%) | |
| AFP level, median (ng/mL) |
9.7 (1.0–19210.5) |
10.9 (1.0–4599.8) |
7.7 (1.5–19210.5) |
0.107 |
| Albumin/bilirubin (ALBI) grade |
0.812 | |||
| Grade 1 | 15 (24.6%) | 10 (23.8%) | 5 (26.3%) | |
| Grade 2 | 44 (72.1%) | 31 (73.8%) | 13 (68.4%) | |
| Grade 3 | 2 (3.3%0 | 1 (2.4%) | 1 (5.3%) | |
| Target therapy after TACE |
7 (11.5%) | 5 (11.9%) | 2 (10.5%) | 0.292 |
| Mean number of prior TACE |
1.16±1.12 (0–4) |
1.71±1.11 (0–4) |
1.53±1.17 (0–4) |
0.550 |
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; ECOG, Eastern Cooperative Oncology Group; EHC, extrahepatic collateral; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; TACE, transarterial chemoembolization.